Condition
Biphasic Mesothelioma|Epithelioid Mesothelioma|Peritoneal Malignant Mesothelioma|Pleural Biphasic Mesothelioma|Pleural Epithelioid Mesothelioma|Pleural Malignant Mesothelioma|Pleural Sarcomatoid Mesothelioma|Recurrent Peritoneal Malignant Mesothelioma|Recurrent Pleural Malignant Mesothelioma|Sarcomatoid Mesothelioma
Estimated Enrollment: 65
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment
Study ID Numbers: IRB14-1381|NCI-2015-00348|P30CA014599
Study First Received: March 13, 2015
Last Updated: November 14, 2016
Estimated Primary Completion Date: March 2018
Primary Outcome Measures:
Ability of PD-L1 to predict response|Overall survival (OS)|Progression free survival (PFS)|Disease control rate (CR + PR + SD)
Sponsors and Collaborators:
University of Chicago|National Cancer Institute (NCI)
Website Link: https://ClinicalTrials.gov/show/NCT02399371
